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Abstract
Background: Modulation factor (MF) and pitch have an impact on Helical TomoTherapy (HT) plan quality and HT
users mostly use vendor-recommended settings. This study analyses the effect of these two parameters on both
plan quality and treatment time for plans made with TomoEdge planning software by using the concept of Pareto
optimal fronts.
Methods: More than 450 plans with different combinations of pitch [0.10–0.50] and MF [1.2–3.0] were produced.
These HT plans, with a field width (FW) of 5 cm, were created for five head and neck patients and homogeneity
index, conformity index, dose-near-maximum (D2), and dose-near-minimum (D98) were analysed for the planning
target volumes, as well as the mean dose and D2 for most critical organs at risk. For every dose metric the median
value will be plotted against treatment time. A Pareto-like method is used in the analysis which will show how
pitch and MF influence both treatment time and plan quality.
Results: For small pitches (≤0.20), MF does not influence treatment time. The contrary is true for larger pitches
(≥0.25) as lowering MF will both decrease treatment time and plan quality until maximum gantry speed is reached.
At this moment, treatment time is saturated and only plan quality will further decrease.
Conclusion: The Pareto front analysis showed optimal combinations of pitch [0.23–0.45] and MF > 2.0 for a FW of
5 cm. Outside this range, plans will become less optimal. As the vendor-recommended settings fall within this
range, the use of these settings is validated.
Introduction
Differences between most common planning systems
have been extensively investigated in planning studies
using statistical [1–9]. However, this method is suscep-
tible to planner’s experience and consequently results
can be biased [10]. New concepts, like Pareto optimal
fronts, can be used as a more robust plan comparison
tool as it gives a more objective evaluation of contradict-
ory objectives [11].
A Pareto front is the collection of Pareto optimal solu-
tions. Because inverse planning makes use of contradict-
ory objectives, high and uniform target dose on the one
hand and sparing of organs at risk (OARs) on the other,
a Pareto front analysis is well suited for showing optimal
combinations in a multi-objective optimization [12–15].
To create a Pareto front, a database of Pareto optimal
plans must be made. A Pareto optimal solution is ob-
tained when one objective cannot be improved without
deterioration in another. Therefore, the concept can be
directly used in inverse treatment planning (as imple-
mented by RaySearch [RaySearch Laboratories, Stockholm,
Sweden] in their multi criteria optimization software, called
RayStation).
In contrast to a multi objective optimization, this
study only uses the concept of Pareto optimal fronts for
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analysis to investigate the impact of Helical TomoTher-
apy’s (HT) specific plan parameters, pitch and modula-
tion factor (MF), on plan quality. The complicated head
and neck (H&N) region, with radiosensitive OARs situ-
ated close to rather radio resistant target volumes, repre-
sents an ideal platform for this study.
The HT planning software requires unique parameters
to be set (field width, pitch and MF) that influences plan
quality. The field width (FW) is defined as the axial thick-
ness of the fan beam and a smaller FW allows more modu-
lation in cranial-caudal direction. The pitch is defined as
the couch travel distance for a complete gantry rotation
relative to the axial beam width at the axis of rotation. Usu-
ally, a pitch of 0.86/n, where n is an integer, is used to re-
duce the thread effect [16]. The MF is defined as the
maximum leaf opening time divided by the average (non-
zero) leaf opening time and it is an estimate of plan com-
plexity. The planning MF can be set as an input in the
planning system. The actual MF indicates the required
complexity of the plan and is limited by the planning MF.
Only planning MF is considered in this study. Most com-
mon settings for a H&N treatment are: FW= 2.5 cm, pitch
= 0.287, MF = ≈3.0 [16]. For treatment planning, the con-
tinuously rotating fan beam with binary multi leaf collima-
tor (MLC is open or closed) is discretized in 51 beams per
rotation. Per angle dose is delivered via the concept of
beamlets.
The latest software version of the HT planning system
has the TomoEdge Dynamic Jaws option allowing the jaws
to open dynamically at the cranial and caudal edges of the
target volume. As TomoEdge creates for every FW (2.5 cm
or 5 cm) a cranio-caudal dose gradient at the beginning
and end of the PTV as sharp as a 1 cm field, treatment
times can be reduced by selecting a larger FW without in-
creasing the integral dose to the patient [17, 18].
This study explores the influence of the HT-specific pa-
rameters (pitch and MF) on plan quality and treatment
time for a FW of 5 cm when fixed optimization constraints
are used. The concept of Pareto optimal fronts is used for
analysis and this analysis will explore whether the widely




For five patients with locally advanced oropharyngeal can-
cer, plans with varying combinations of pitch and MF have
been made. CT scans and contours were adopted from a
previous study [9].
For every patient a set of HT plans was made using a
HT Planning Station – TomoHDA Version 2.0.0. This
set contains one reference plan and plans for creating
the Pareto optimal front. The reference plan (REF5cm)
was fully optimized to our current practice using
standard settings (FW = 5 cm, pitch = 0.430 and MF =
2.8). To obtain plans for the Pareto front analysis, this
reference plan and its optimization constraints were
copied and pitch and MF were varied in nine steps
within the range [pitch = 0.10–0.50] and ten steps within
the range [MF = 1.2–3.0], respectively. This resulted in
90 treatment plans per patient, each with a unique com-
bination of pitch and MF. The chosen ranges of pitch
and MF are limited by our clinically used settings. For
comparison, a second reference plan (REF2.5 cm) was
produced (FW = 2.5 cm, pitch = 0.287 and MF = 2.8).
For each plan used to help generate the Pareto optimal
front the same constraints were used during an
optimization process of 200 iterations, which differs from a
full multi-objective optimization. No interaction during the
optimization process was allowed in order to avoid planner
induced biases, except for the REF plans.
The dose distributions were calculated with voxel-less
optimization (VoLO) [19], using a convolution/superpos-
ition algorithm [20] and a normal grid size of 3.8 mm ×
3.8 mm.
Prescription
A simultaneous integrated boost technique was planned to
deliver a dose of 69.12 Gy (2.16 Gy/fraction) in 32 fractions
to the therapeutic planning target volume ‘PTV69’ and a
dose of 56 Gy (1.75 Gy/fraction) to the elective ‘PTV56’.
Each reference plan was set to respect the prescription
guidelines of the International Commission on Radiation
Units and Measurements (ICRU) report 83 [21], and the
dose to all OARs had to be kept as low as possible.
Data reporting
For each patient multiple combinations of pitch and
MF were generated. Several specific and critical doses
and irradiated volumes of different OARs (mean dose
[Dmean] and dose-near-maximum [D2 %, dose re-
ceived by 2 % of the tissue]) and PTVs (homogeneity
index [HI, (D2 %-D98 %)/Dprescribed], conformity index
[CI, V95 %Dprescribed(body)/V95 %Dprescribed(PTV)], dose-
near-minimum [D98 %, dose received by 98 % of the
tissue] and D2 %) were calculated with an in-house
written Matlab program. Treatment times were also
reported.
Data analysis
For these five H&N patients, representing a class solu-
tion for each unique combination of pitch and MF, a
median value was calculated for every reported OAR/
PTV dose and index (HI, CI, D98, D2 and/or Dmean).
Out of this inter patient median value different Pareto-
like fronts have been created to show the influence of
MF and pitch on both treatment time and the chosen
dose value.
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Results
The Pareto fronts of the OARs and the target volumes
as shown in Figs. 1a, 1b and 2 were calculated out of
450 plans (90 plans produced per patient, each with a
different combination of pitch and MF). Only the data
points that lie on top of the black Pareto line approxi-
mate the Pareto optimal front. In addition to the Pareto
front, data from a previous study [9], containing both a
‘standard’ HT plan (FW 2.5 cm, pitch 0.287, MF 2.8 for
TomoHD, version 1.0.0; HT data point) and a RapidArc
plan (2 full arcs, version 8.6.15; RA data point), are
added to these graphs as reference points.Figure 1b gives
a more detailed view on how data points behave, related
to a changing pitch or MF.
Treatment time
Treatment time was reduced by almost 50 % when a FW
of 5 cm was used compared to the (standard) FW of
2.5 cm (Fig. 1), at the cost of a less optimal dose distribu-
tion [22]. The REF5cm field has a median treatment time
of 3.7 min. For 5 cm fields, treatment time varies with
varying pitch and MF. The low pitches (≤0.20) show a con-
stant treatment time, independent of the chosen MF.
Higher pitches (≥0.25) have a dual behaviour. Initially, low-
ering MF will decrease both treatment time and plan qual-
ity. Subsequently, treatment time becomes invariable and
only dose is further influenced by the varying MF. The sat-
uration point, defined at the transition of these two states,
occurs for every pitch at a different MF as plotted in Fig. 3.
Target volumes
PTV69 has a very homogenous and conformal dose distri-
bution for all plans regardless of pitch, MF or FW (Fig. 2).
HI decreases (lower HI =more homogeneous) with de-
creasing pitch or increasing MF, CI only changes for the
very small pitches (0.10–0.25). For pitches larger than 0.25
the conformity index decreases (plans become more and
more conformal) with increasing MF until the MF be-
comes higher than 2.6 or 2.8. D98 also increases with in-
creasing MF for both PTV56 and PTV69. The opposite is
true for D2.
OARs
For all OARs, Pareto fronts can be created, except for
the oral mucosa and the skin near PTV, as shown in
Fig. 1. Dose to the OARs is influenced by both pitch and
MF. The largest dose reduction is introduced when in-
creasing the MF from 1.2 to 1.4 or 1.6. Plans with MF ≤
1.4 can be classified as clinically unacceptable because of
a too high dose to the spinal cord.
Discussion
Due to the large number of plans, patient specific Pareto
fronts with HT planning software is labour intensive.
Consequently, the Pareto optimality approach is difficult
to use in clinical practice. However, general trends that
can be applied in daily routine can be deduced from
studies such as this.
A TomoEdge plan (FW of 5 cm) yielded no improve-
ment in plan quality when compared to a plan with a FW
of 2.5 cm, as TomoEdge only moves jaws at both edges of
the PTV in cranio-caudal direction and not during the rest
of the treatment. Consequently, dose penumbra will only
be reduced at the outer edges of the treatment volume [18,
23]. During treatment, dose reduction in the OARs is lim-
ited to the modulation capabilities of the 5 cm field. Be-
cause a plan with a 2.5 cm FW can use more beamlets,
and thus more optimization possibilities, than a plan with
a 5 cm field when treating the same volume, better sparing
of the OARs is possible with a smaller FW.
The smallest pitches (0.10 and 0.15) yield no improve-
ment compared to 2.5 cm fields, as the latter result in
faster and better plans (lower doses to all OARs). These
low pitches show a constant treatment time, independ-
ent of the chosen MF, as the gantry period already
reached its minimal value of 12 s. This can be explained
by the overshoot in optimization possibilities (eg: for a
pitch of 0.10, each voxel within the target volume can be
optimized by 510 beamlets). A lower MF will only result
in a worse dose distribution and a higher dose to the
normal tissue. The latter is also valid for a pitch of 0.20
with the exception of its faster treatment time.
Pitches of 0.25 or higher first show a constant behav-
iour for small MFs (dots lie on a horizontal line), treat-
ment time is unaffected by an initial increase in MF.
Once the minimal gantry period becomes too short to
obtain enough modulation for a given MF, treatment
time increases with increasing MF. The dose distribution
to OARs/PTVs also improves with increasing MF. Below
the minimal gantry period, further reduction of MF can-
not accelerate gantry speed anymore and consequently
treatment time becomes invariable and only dose distri-
bution will vary. A relationship exists defining the min-
imal MF that should be used for a given pitch. This
relationship is shown in Fig. 3 and can be predicted by
MF = 20∗ pitch2 − 21∗ pitch + 6.8 with norm of resid-
uals = 0.12 and pitch∈ {0.25 − 0.50} and shows a plateau
at pitch ~0.23. This means that for the widely used pitch
of 0.430 [16] (for a 5 cm FW), the optimal MF must be
larger than 1.5. Below this value, no further gain in treat-
ment time will occur, hence the dose distribution will only
become worse.
Oral mucosa and skin near PTV do not show a Pareto
front because their mean doses are almost constant (42-
43Gy and 45-46Gy, respectively) for every combination
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Fig. 1 (See legend on next page.)
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of pitch and MF. Due to the major spatial overlap be-
tween oral mucosa and PTV, changes in pitch and MF
can arbitrarily only slightly increase or decrease the
mean dose. The latter is also true for the skin near PTV
as the mean dose of this OAR is almost uninfluenced by
a varying pitch or MF.
The Pareto fronts of the PTVs show two important ef-
fects. First, for pitches ≥0.30 the CI of PTV69 decreases/
becomes better with increasing MF until the MF be-
comes higher than 2.6 or 2.8, depending on the used
pitch. This sudden increase of the CI is due to a too high
conformity of the plan. Because the CI looks for the
95 % isodose coverage of the PTV, the index becomes
inferior when the PTV is completely covered by, for ex-
ample, the 98 % isodose level. Secondly, the homogen-
eity of PTV56 is less than PTV69, because it depends on
the location of the dose gradient. In these 2 dose level
plans, the gradient can be placed either inside PTV56 or
inside PTV69 as depicted in Fig. 2, or anywhere in be-
tween both extremes.
Fig. 2 Target volume Pareto fronts of conformity index, homogeneity index, D2 and D98 for PTV56 and PTV69. Every colour represents a single
pitch and per colour the subsequent dots (dot = median value) represent a change in MF. The arrow points at increasing MF (for D98 the arrow
is reversed). Dots lying on top of the black solid line are Pareto optimal
(See figure on previous page.)
Fig. 1 a: OAR Pareto fronts (from left to right and top to bottom) of D2 for PRV cord and PRV brainstem and for the mean dose of oral mucosa,
heterolateral parotid gland, homolateral parotid gland, oesophagus, lower pharyngeal constrictor, middle pharyngeal constrictor, cricopharyngeal
muscle, glottic larynx, supraglottic larynx and skin near PTV. Every colour represents a single pitch and per colour the subsequent dots (dot =
median value) represent, from right to left, an increasing MF. Dots lying on top of the black solid line are Pareto optimal.b: Pareto front of Body
mean dose.
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The Pareto fronts cover a wide range of Pareto optimal
combinations: from pitch 0.10 and MF 3.0 to pitch 0.50
and MF 1.2. Despite the Pareto optimality of these
points, not all of them result in clinically acceptable
plans. The combination of a large pitch (0.50) and a low
MF results in Pareto optimal combinations with clinic-
ally unacceptable doses to OAR. On the other side of
the Pareto front, small pitches (0.10–0.20) introduce too
much overlap between adjacent fan beams to be of any
added value and consequently less modulation per rota-
tion is required to end up with the same result. This ex-
cess of modulation leads to an unnecessary increase in
monitor units and irradiation time, as confirmed in
other studies [24, 25]. This Pareto front analysis shows
that for a FW of 5 cm clinically acceptable combinations
exist if pitch is chosen in a range of [0.23–0.45] and
MF > 2.0. These values represent the best trade-offs be-
tween low OAR dose, PTV HI and CI and treatment
time. The corresponding treatment time can vary from
4 m 05 s to 2 m 45 s.
The actual created Pareto fronts can be a good guide-
line in the planning of standard HT plans, increasing the
intuitive understanding of how pitch and MF mutually
interact with plan quality. However, patient-specific fine-
tuning is still required in radiotherapy treatment plan-
ning. Because this study is not a complete multi-criteria
optimization, plans superior to the shown Pareto fronts
can be made by using a different optimization technique
and/or a different delivery technique. Nevertheless, our
study can help to minimize this time consuming fine-
tuning and can serve as a planner’s reference in difficult
cases.
Conclusion
This study validates the vendor-recommended, default
settings (pitch 0.430, MF ≈ 3.0 for FW 5 cm) as they fall
in the trade-off range of most optimal combinations of
pitch and MF and the REF5cm plan closely approxi-
mates the Pareto optimal fronts. However, by decreasing
pitch there could be further improvement of plan quality
(and increased treatment time) until pitch approaches
~0.23, with no reason to lower pitch beyond this value.
As for every pitch a lower threshold for the correspond-
ing MF is proposed where saturation in treatment time
versus plan quality space occurs, plan quality only dete-
riorates without a gain in treatment time if MF is below
this limit. It is up to the planner/radiation oncologist to
decide what the best trade-off is along this curve within
the range of [0.23–0.45] as long as MF > 2.0 for a FW of
5 cm.
As this study uses 5 oropharyngeal cancer patients to
represent ‘the difficult case which best shows the possi-
bilities of Helical Tomotherapy’, the authors believe the
conclusions can be extrapolated towards other indica-
tions which require equal or less modulation.
Fig. 3 Plot of saturation point (gantry period becomes minimal), as a function of pitch and MF. Quadratic fit through 6 largest pitches
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